More than 100 countries around the world are vaccinating children against COVID-19.
More than 100 countries around the world have expanded their COVID-19 vaccination campaigns for children.
According to a UNICEF report, which analyzed 115 million confirmed COVID-19 cases from 105 countries, people under the age of 20 account for 16 percent of the reported cases.
While many children who catch COVID have few or no symptoms, those with underlying health conditions may be at increased risk of serious illness.
Three vaccines approved by the World Health Organization (WHO) are being given to children in different countries: the Pfizer-BioNTech vaccine, the SinoPharm shot and the Sinovac vaccine.
While some countries are offering children and adolescents a full two-dose course of the Pfizer-BioNTech vaccine, others are offering a single dose.
According to the London School of Hygiene and Tropical Medicine, there are 20 vaccine candidates in clinical trials for people under the age of 18.
China has started vaccinating children aged three years and older with its own CoronaVac vaccine manufactured by Sinovac Biotech.
Taiwan temporarily suspended the second dose of the Pfizer-BioEntech vaccine to children and adolescents aged 12 to 17 years due to concerns about the risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer layer of the heart). Is. for the media reports,
In August, India’s drug regulator approved Zydus Cadila’s needle-free ZyCoV-D vaccine for people aged 12 years and above. It is the world’s first DNA-platform vaccine for COVID-19, but its rollout has not started. Bharat Biotech, maker of the domestically manufactured Covaxin vaccine, sought permission for emergency use in children 12 years of age and older, but regulators have yet to announce a decision. Vaccinations for certain groups of children may begin in January, news reports Say,
Pakistan is currently giving the Pfizer-BioNTech vaccine to children above 15 years of age and Chinese Sinovac and Sinopharm vaccines to children above 12 years of age.
South Africa began immunizing children aged 12 to 17 in October. The government is aiming to vaccinate nearly six million adolescents in this age group with a single dose of the Pfizer-BioNTech vaccine.
Morocco, one of the first African countries to give shots to children and adolescents, began immunizing people aged 12 to 17 in September. It is using Pfizer-BioNTech and SinoPharm vaccines with an aim to vaccinate at least 3 million children.
The European Union’s health regulator, the European Medicines Agency (EMA), in May approved the use of the Pfizer-BioEntech vaccine for use in children over the age of 12.
In Germany, as of November 23, about 45 percent of people aged 12 to 17 were fully vaccinated with the Pfizer-BioNTech vaccine.
In Norway, which is not part of the European Union, the Pfizer-BioNTech vaccine is approved for people aged 12 to 15 years. But health officials have halted the rollout of the second dose, partly because of a rare side effect linked to inflammation of the heart.
In the United Kingdom, which is not part of the EU, a single Pfizer-BioNtech jab is being offered to 12 to 15-year-olds.
EU regulators are evaluating an application to expand the use of the vaccine to children aged five to 11 years. It is expected to be announced next month.
In September, Cuba began introducing vaccines with the domestically produced Sobrana-02 and Sobrana Plus vaccines for children under the age of two.
In Venezuela, officials announced in early November that vaccinations were underway for children under the age of two using Cuba’s Sobrana-02 shot.
Brazil’s health regulator Anvisa has approved the use of the Pfizer-BioNTech vaccine in children aged 12 to 17, and the government has encouraged local authorities to prioritize those children and adolescents.
The United Arab Emirates began its immunization campaign in August with the Sinoform vaccine in children aged three to 11 years. In November, Emirati authorities approved the Pfizer-BioNTech vaccine for children aged five to 11 years.
In October, Bahrain authorized the use of the Sinoform shot for children aged three to 11. This month, it approved the use of Pfizer-BioNtech for children between the ages of five and 11.
United States of america
In May, US health officials approved the Pfizer-BioNTech vaccine for use in children between the ages of five and 17.
Since the start of the pandemic, representation of children According to the American Academy of Pediatrics, 16.9 percent of all confirmed cases. In the week ending November 18, children made up 25.1 percent of the reported cases. Children make up 22.2 percent of the US population.